Products for Research Use Only

Tofogliflozin hydrate

CAT: 0013-GTR19164322-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19164322-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tofogliflozin (CSG-452) is a potent, highly selective SGLT2 inhibitor with Ki of 2.9, 14.9, and 6.4 nM against human, rat, and mouse SGLT2, respectively; displays high selectivity over human SGLT2 versus human SGLT1, SGLT6, and sodium/myo-inositol transporter 1; increases renal glucose clearance and lowered the blood glucose level in Zucker diabetic fatty rats, also improves postprandial glucose excursion; reduces glycated hemoglobin and improved glucose tolerance in the oral glucose tolerance test in vivo.Diabetes Approved (In Vitro) :Tofofloxacin (3-30 nM; 24 hours; tubular epithelial cells) treatment inhibits the oxidative stress generation and monocyte chemoattractant protein-1 (MCP-1) gene expression in tubular cells induced by high glucose.Tofofloxacin (3-30 nM; 8 days; tubular epithelial cells) treatment inhibits the apoptotic cell death induced by high glucose. (In Vivo) :Tofogliflozin (0.1-10 mg/kg; oral administration; once daily; for 4 weeks; db/db mice) treatment improves hyperglycemia and thereby ameliorated glucose intolerance of the obese diabetic mice.
CAS Number
1201913-82-7
Product Name Alternative
CSG452 hydrate | CSG-452 hydrate
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
CCC1=CC=C (C=C1) CC2=CC3=C (COC34C (C (C (C (O4) CO) O) O) O) C=C2.O
Molecular Formula
C22H28O7
Molecular Weight
404.5
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Spiro[isobenzofuran-1 (3H),2'-[2H]pyran]-3',4',5'-triol, 6-[ (4-ethylphenyl) methyl]-3',4',5',6'-tetrahydro-6'- (hydroxymethyl) -, hydrate (1:1), (1S,3'R,4'S,5'S,6'R) -